ArticleFrontiers in cardiovascular medicine2025
Efficacy of ivabradine in patients with poor heart rate control after beta-blocker use in acute myocardial infarction: a pragmatic randomized controlled trial.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Heart rate management using ivabradine in acute myocardial infarction: a propensity score-matched single-center study.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A rapid resting heart rate following acute myocardial infarction (AMI) predicts poor prognosis, making heart rate control crucial in treatment. Ivabradine is commonly used as a second-line therapy when beta-blockers are poorly tolerated. However, its efficacy in improving cardiac function and prognosis compared to beta-blockers alone remains unclear. This study aimed to investigate the efficacy of ivabradine in the "real world" in patients with AMI who exhibited poor heart rate control despite beta-blocker therapy. Methods: A total of 1,632 patients with AMI were screened, and 104 patients with resting heart rate >70 bpm after beta-blocker use were randomized in a 1:1 ratio into two groups: the ivabradine ( Results: There were no statistically significant differences in age, sex, risk factors, cardiac function class, blood pressure, heart rate, and comorbid medications between the two groups at the time of enrollment ( Discussion: In "real-world" patients with AMI and poorly controlled heart rate despite titration of beta-blocker dosing, ivabradine was safe and effective in controlling heart rate and improving LVEF early after discharge. However, it had no effect on the 12-month incidence of hospitalization for heart failure and cardiovascular death after discharge.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.